Metraipolis › archive › dc_efdc3e048d61

Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes — Europe PMC PMID:42439602

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42439602
DOI
10.1080/07853890.2026.2696636
License (as archived)
solo-consultazione
Archived
2026-10-08T03:03:29.427Z
SHA-256 of the archived text
84aab307f1ca2e0a35572aca7cf27d495f0dd330a8c4e759c38ceb5b8df13278
Stable URL of this page
https://metraipolis.com/documento/dc_efdc3e048d61

How to cite

Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes — Europe PMC PMID:42439602 — Europe PMC (en), https://europepmc.org/article/MED/42439602 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_efdc3e048d61 (Metraipolis archive dc_efdc3e048d61, sha256 84aab307f1ca2e0a35572aca7cf27d495f0dd330a8c4e759c38ceb5b8df13278)
BibTeX
@misc{dcefdc3e048d61,
  title = {Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes — Europe PMC PMID:42439602},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42439602},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_efdc3e048d61; sha256 84aab307f1ca2e0a35572aca7cf27d495f0dd330a8c4e759c38ceb5b8df13278},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42439602. Agents can read the archived copy with the MCP tool read_document.